Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Commercial Companies

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

  • Analysis

Executive Summary

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

You may also be interested in...



Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial

Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Exelixis CEO Eyes Expanded Indications For Cabozantinib

In a video interview at the Biotech Showcase, Exelixis CEO Michael Morrissey discusses the recent launch of cabozantinib in first-line renal cell carcinoma and looks ahead to filing soon in liver cancer.

Ipsen Pays $575m Upfront For Struggling Pancreatic Drug Onivyde

Ipsen's new CEO David Meek has conducted the French company's biggest ever deal by acquiring Onivyde for pancreatic cancer from Merrimack Pharmaceuticals, and believes Ipsen will turn Onivyde's fortunes around.

Table

View full table

Topics

Related Companies

Tags:
Business Strategies Commercial Companies
Latest Headlines

Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs

Executives On The Move: Jubilant, Mithra And More

From Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs

Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi

See All
UsernamePublicRestriction

Register

SC100408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By